FindTrial
Sign In

Diagnostic exam for renal cancer

Prospective evaluation of the use of PET/CT with 18 F-PSMA in kidney cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-6p8pkvq
Enrollment
Unknown
Registered
2023-07-26
Start date
2023-01-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cancer

Interventions

Observational, unicentric study, with prospective data collection, which will be developed in the Nuclear Medicine and Urology Departments of the ACCamargo Cancer Center. A total of 30 patients with h
V03.175.500

Sponsors

Fundação Antônio Prudente - AC Camargo Cancer Center
Lead Sponsor
Fundação Antônio Prudente - AC Camargo Cancer Center
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients aged at least 18 years; both genders; with histopathological diagnosis of renal cancer, clear cell or papillary subtypes

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
To evaluate the diagnostic capability of 18F-PSMA PET/CT in patients with renal cancer compared to conventional exams and 18F-FDG PET/CT based on the use of standardized uptake value (SUV)—

Secondary

MeasureTime frame
No secondary outcomes are expected—

Countries

Brazil

Contacts

Public ContactEduardo Lima

AC Camargo Cancer Center

eduardo.lima@accamargo.org.br+55(11)21895000, Ramal 2832

Outcome results

None listed

Source: REBEC (via WHO ICTRP)